Aardvark Therapeutics, Inc. (NASDAQ:AARD – Get Free Report) has received a consensus recommendation of “Hold” from the nine research firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $11.06.
A number of analysts have recently weighed in on AARD shares. Raymond James Financial reaffirmed a “market perform” rating on shares of Aardvark Therapeutics in a research report on Friday. UBS Group set a $4.00 price target on shares of Aardvark Therapeutics in a research report on Monday, October 19th. Oppenheimer lowered shares of Aardvark Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, October 26th. HC Wainwright cut their price objective on shares of Aardvark Therapeutics from $4.00 to $2.00 and set a “hold” rating on the stock in a report on Monday, October 26th. Finally, Stifel Nicolaus set a $2.00 target price on shares of Aardvark Therapeutics in a research note on Monday.
Check Out Our Latest Analysis on AARD
Insider Activity at Aardvark Therapeutics
In other news, insider Nelson Sun sold 62,000 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $5.18, for a total value of $321,160.00. Following the sale, the insider directly owned 35,475 shares of the company’s stock, valued at $183,760.50. The trade was a 63.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 17.80% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AARD. BlackRock Inc. bought a new position in Aardvark Therapeutics in the 2nd quarter valued at approximately $1,077,000. Marshall Wace LLP boosted its stake in Aardvark Therapeutics by 593.0% during the 3rd quarter. Marshall Wace LLP now owns 132,204 shares of the company’s stock valued at $697,000 after purchasing an additional 113,128 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Aardvark Therapeutics during the 1st quarter valued at $267,000. J. Goldman & Co LP bought a new stake in shares of Aardvark Therapeutics in the 2nd quarter worth $233,000. Finally, Ieq Capital LLC bought a new stake in shares of Aardvark Therapeutics in the 2nd quarter worth $221,000.
Aardvark Therapeutics Stock Down 5.3%
NASDAQ:AARD opened at $1.26 on Thursday. The firm’s fifty day simple moving average is $3.68 and its 200 day simple moving average is $5.66. The stock has a market cap of $27.57 million, a P/E ratio of -0.38 and a beta of 4.38. Aardvark Therapeutics has a twelve month low of $0.93 and a twelve month high of $16.60.
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last issued its quarterly earnings data on Friday, November 13th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.19). On average, analysts expect that Aardvark Therapeutics will post -3.05 EPS for the current fiscal year.
Aardvark Therapeutics Company Profile
Aardvark Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops oral medicines for metabolic disorders, with a focus on conditions involving excessive hunger and disrupted energy balance. The company’s lead candidate, ARD-101, is an investigational oral therapy designed to activate bitter taste receptors in the gut and influence gut-brain signaling. Aardvark has studied the candidate for hyperphagia, or excessive hunger, associated with Prader-Willi syndrome and hypothalamic obesity.
See Also
- Five stocks we like better than Aardvark Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
